hotspot -WSS

hotspot

author：comprehensive 2025-09-30 00:46:21 - browse：4

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Bluebird, CVS, Contineum

explore

WSS

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Stem cell treatment guidelines are released by FDA

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

'Make People Better': The CRISPR babies story you probably don't know

A rare thyroid diagnosis led to unexpected, all

Weighted lottery helped low

entertainment

hotspot

Sign up for D.C. Diagnosis

entertainment

Walensky prepares to leave CDC — and Congress — behind

Orchard's therapy for neuron disease in children wins FDA approval

Continuity nursing helped my family in our darkest PICU moments

How generative AI is inspiring dreams of a health data revolution

The high cost of giving birth even with insurance

App could help diagnose ear infections more accurately — and at home

Activists slam private health insurers over coverage restrictions

SCOTUS questions limit to govt efforts to fight misinformation

Jerome Adams on the need for new antivirals for Covid

Gene editing the human germline: What are the risks?

leisure time

Illumina names Agilent executive as new CEO

Plastic surgeons increase patient psychiatric screenings

What American doctors can learn from their Israeli counterparts

Listen: Biogen's potential pivot, & Illumina's next chapter

UnitedHealth increases loan offers after Change Healthcare outage

Weighted lottery helped low

explore

focus

explore

leisure time